72 results about "Acyl coenzyme" patented technology

The invention relates to a molecule marking method for pig backfat thickness property. The method comprises: extraction of pig genome DNA, design of a long-chain acyl-coenzyme Asynthetase 1 (ACSL1) gene seventh exon primer, amplification in vitro and genotype detection. For the first time, it is discovered that the polymorphism of the long-chain acyl-coenzyme Asynthetase 1 (ACSL1) gene seventeenth exon has significant correlation with the pig backfat thickness, and a method for detecting the restriction fragment polymorphism at mutation sites of the seventeenth exon is established. The molecule marking method is applicable to auxiliary selection on backfat thickness property during breeding of pigs, helps to realize early-stage breeding selection of boars, and even helps to accurately select breeding just when pigs are born, so that the generation interval is shortened, and the selection progress of the backfat thickness property is accelerated; and the method is simple in operation, condition requirements during a polymerase chain reaction are low, the length of amplified fragments is relatively short (292 bp), amplification is relatively easy, and the method helps to improve amplification efficiency and accuracy of genotype determining.

The present invention relates to the field of medical technology, and in particular relates to a category of novel sulphonyl substituted xanthene ketone compounds that have a structural formula as shown in the right, a preparation method and application thereof. The compound has high inhibitory activity for ACAT1/ACAT2; most of the compounds have high inhibitory activity for acyl coenzyme A cholesterol acyltransferase (ACAT). The compounds can be used for preparing anti-atherosclerosis drug combination. Furthermore, the compounds can be used as a preventive or a treating agent of such diseases as angina, myocardial infarction, cerebral infarction, apoplexy, Alzheimer's disease, acute coronary syndrome, PTCA or restenosis of coronary artery after a bracket is arranged. The compounds can be used as a treating agent to adjust the function of sebaceous glands of the skin and inhibit the excessive generation of sebum. And the compounds can be used for treating such diseases as acne-like damage caused by oily skin, acne, seborrhea and corticosteroids.

Recombinant microbial cells are disclosed herein that produce an oil comprising at least 28 percent eicosapentaenoic acid (EPA) measured as a weight percent of dry cell weight. These cells may comprise a polynucleotide sequence encoding an active acyl-CoA:lysophosphatidylcholine acyltransferase (LPCAT) comprising at least one amino acid mutation in a membrane-bound O-acyltransferase motif. In addition, the cells may comprise a down-regulation of an endogenous polynucleotide sequence encoding Sou2 sorbitol utilization protein, and/or one or more polynucleotides encoding phospholipid:diacylglycerol acyltransferase (PDAT), delta-12 desaturase, a dihomo-gamma-linolenic acid (DGLA) synthase multizyme, delta-8 desaturase, malonyl-CoA synthetase (MCS), or acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT). Also disclosed are methods of using the recombinant microbial cells to produce oil containing omega-3 polyunsaturated fatty acids such as EPA.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

A compound of the formula (I):wherein Ring A is substituted or unsubstituted pyridine ring, Y is substituted or unsubstituted alkyl, etc., R1 is hydrogen, or substituted or unsubstituted alkyl, etc., R2 is hydrogen or lower alkyl, R3 is lower alkyl, Z is1) -D1-Q [D1 is direct bond or divalent C1-8 hydrocarbon, etc., Q is hydroxy, carboxyl, etc.], or2) -D2M-E-W [D2 is direct bond or divalent C1-8 hydrocarbon, etc., M is oxygen, sulfur, etc., E is direct bond or divalent C1-8 hydrocarbon, etc., W is hydroxyl, carboxyl, etc.],or a prodrug thereof, or a pharmaceutically acceptable salt of the same, which exhibits acyl-CoA: cholesterol acyl transferase (ACAT) inhibitory activity, and is useful as an agent for treatment of hyperlipidemia and atherosclerosis.

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention discloses new application of a substance for inhibiting genetic expression and/or protein activity of acyl coenzyme A/cholesterol acyltransferase-1. According to the application, the inhibitor can be used for preparing drugs for preventing and/or treating cancer; the inhibitor can be used for preparing drugs for preventing and/treating cancer spreading and metastasis; the inhibitor can be used for preparing drugs for promoting apoptosis of cancer cells; the inhibitor can be used for preparing drugs for inhibiting cancer cells from being transformed into cancer; the inhibitor canbe used for preparing drugs for inhibiting in vitro proliferation growth of the cancer cells. Through experiments, the inventor proves that the acyl coenzyme A/cholesterol acyltransferase-1 (ACAT1/SOAT1) is obviously highly expressed in liver cancer tissue, and the high enrichment value of the acyl coenzyme A/cholesterol acyltransferase-1 shows that prognosis of a liver cancer patient is poor. TheACAT1/SOAT1 inhibitor can effectively inhibit growth of human liver cancer cells and other cancer cells in the cellular level, and the inhibitor can used as a candidate drug target of cancers, especially the liver cancer.

The invention relates to the technical field of biology and discloses a method for heterologous biosynthesis of tonquinol, caffeol and ferulenol. The metabolic pathway for production of tonquinol, caffeol and ferulenol is added into hosts. More precisely, tyrosine ammonia lyase, cinnamoyl-coA reductase, alcohol dehydrogenase and coumaric acid coA ligase are efficiently expressed in the host for producing tonquinol, 4-hydroxyphenylacetic acid3-monooxygenase is added to produce caffeol, coffee acyl coenzyme AO-methyl transferase or caffeic acid O-methyl transferase is added to produce ferulenol. Genes coded by the enzyme are guided into the host, and the production host of tonquinol, caffeol and ferulenol can be generated by means of glucose. The invention further discloses a method for co-culture of different hosts, and the caffeol and the ferulenol are produced more efficiently.

This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a fatty acid or fatty acid derived product, wherein the modified microorganism produces fatty acyl-CoA intermediates via a malonyl-CoA dependent but malonyl-ACP independent mechanism.

The invention discloses a breeding method of a laying hen with low egg yolk cholesterol content. The breeding method comprises the following steps of (1) taking a DNA (deoxyribonucleic acid) sequence including chicken HMGCR (Hydroxymethyl glutaric acyl coenzyme) gene as a template, designing a pair of primers, and carrying out sample chicken individual gene parting by a PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) method; (2) utilizing a genetic effect analysis model to determine selected and remained genetype; (3) building a family from individual bodies of cocks and hens according with the selected and remained genetype; (4) extracting the DNA in later generation of the selected and remained family hen, carrying out PCR-RFLP analysis on the pair of primers in step (1), selecting and remaining the hens with selected and remained genetype in step (2); and (5) repeating steps (3) and (4) to continuously breed for at least three generations, so as to obtain the laying hen with low egg yolk cholesterol content. The HMGCR gene molecular marker is adopted to assist and select the breeding method; the generation interval is shortened; the breeding accuracy is improved; the breeding flock feeding capacity is reduced; and the feeding cost is also reduced.

The invention provides a microorganism and an application thereof. The microorganism is used for preparing aliphatic ester. The microorganism comprises a first nucleotide sequence, a second nucleotide sequence, a third nucleotide sequence and a fourth nucleotide sequence, wherein the first nucleotide sequence is used for encoding acyltransferase AT genes or a functional equivalent thereof, and the second nucleotide sequence is used for encoding 2-keto acid decarboxylase ARO10 gene or a functional equivalent of the 2-keto acid decarboxylase ARO10 gene, ethanol dehydrogenase ADH2 genes or a functional equivalent of the ethanol dehydrogenase ADH2 gene and acyl coenzyme A reductase FAR genes or a functional equivalent of the acyl coenzyme A reductase FAR gene; the third nucleotide sequence is used for encoding endoglucanase gene or a functional equivalent of the endoglucanase gene and beta-glucosaccharase gene B-GL or a functional equivalent of the beta-glucosaccharase gene, and the fourth nucleotide sequence is used for encoding acyl-coenzyme A reductase FAR gene or a functional equivalent of the acyl-coenzyme A reductase FAR gene. By utilizing the microorganism, the preparation efficiency of the aliphatic ester can be effectively improved.

The invention discloses an acyl coenzyme A-reductase gene phsR and the application thereof. The acyl coenzyme A-reductase gene phsR has a nucleotide sequence shown as SEQ ID No. 1. The invention also provides an engineering strain with deletion of the acyl coenzyme A-reductase gene phsR. The engineering strain is named as Mycobacterium neoaurum Delta phsR, and has a collection number of CCTCC NO. M2016321. The engineering strain disclosed by the invention is capable of effectively eliminating 4-BNA by-products in the sterol degradation process, obviously improving the purity and the yield of AD, ADD, 9-OH-AD and other series of steroid products prepared by depending on the sterol degradation, reducing the cost of raw materials for producing steroid drugs and the energy consumption, improving the utilization rate of prodrugs and greatly simplifying the preparation process of AD and other steroid drugs, and has a high industrial application value.

The invention discloses saccharomyces cerevisiae highly producing C6-C10 ethyl esters and a construction method and purpose of the saccharomyces cerevisiae, and belongs to the technical field of bioengineering. Through overexpressing acetaldehyde dehydrogenase ALD6 and acetyl-CoA synthase ASC1 in an original strain, synthesis of acetyl-CoA is strengthened, through overexpressing acetyl-CoA carboxylase ACC1**, malonyl CoA is strengthened, through overexpressing fatty acid synthetase FAS1 and fatty acid synthetase FAS2, medium-chain acyl-CoA is strengthened, more metabolism flows flow to medium-chain acyl groups CoA, alcohol acyl-transferase genes SAAT in strawberries are further exogenously introduced, and a reformed strain C-ald6acs1A*F1F2S is obtained. Under the condition of fermentation,the yield of ethyl caproate is 7.53mg/L which is 2.72 times of that of an original strain C-ald6acs1A*F1F2, and 26.89 times of that (only 0.27mg/L) of an original strain CA, the yield of ethyl caprylate is 13.65mg/L which is 9.11 times of that of the original strain CA, the yield of ethyl decanoate is 13.89mg/L which is 7.27 times of that of the original strain, and the saccharomyces cerevisiae has potential application prospects in improving flavor of wine and improving the quality of the wine.

The invention discloses recombinant saccharomyces cerevisiaes, construction methods of the recombinant saccharomyces cerevisiaes and applications of the recombinant saccharomyces cerevisiaes in production of hydroxy fatty acids. Through a homologous recombination method, the recombinant fungi (1) are obtained by knocking out key gene acyl coenzyme A oxidase POX1 in a beta-oxidation pathway relatedto fatty acid catabolism in saccharomyces cerevisiaes and knocking out acyl coenzyme A activating enzymes FAA1 and FAA4, recombinant fungi (2) are obtained by introducing cytochrome P450 oxidase CYP52M1 and cytochrome P450 reductase SbCPR into the recombinant fungi (1), or the recombinant fungi (3) are obtained by introducing cytochrome P450 oxidase CYP52M1 and cytochrome P450 reductase AtCPR1 into the recombinant fungi (1), or the recombinant fungi (4) are obtained by introducing cytochrome P450 oxidase and cytochrome P450 reductase fusion protein gene CYP52M1-AtCPR1 into the recombinant fungi (1).

The present invention provides novel polynucleotides encoding MGAT3 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MGAT3 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, such as obesity. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

The present invention relates to a series of analogues of natural product Pyripyropene A represented by general formula I and a preparation method and use thereof. More particularly, the present invention relates to analogues of the natural product Pyripyropene A, a preparation method and use thereof as the acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors for the treatment of cardiovascular diseases such as atherosclerosis and the like.